{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:22:47Z","timestamp":1791202967921,"version":"4.2.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PMP22\/00022"],"award-info":[{"award-number":["PMP22\/00022"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["RTC2019-006995-1"],"award-info":[{"award-number":["RTC2019-006995-1"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006365","name":"Universidad de Cantabria","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006365","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Friedreich\u2019s ataxia (FRDA) is the most common early onset hereditary ataxia, caused by GAA repeat expansions in the\n                    <jats:italic>FXN<\/jats:italic>\n                    gene. The length of the shorter allele (GAA1) and age at onset are established determinants of disease severity, though additional biomarkers such as frataxin expression and neurofilament light chain (NfL) have been proposed. We conducted a 30-month prospective longitudinal study, including 25 FRDA patients and 16 heterozygous carriers, assessing clinical progression through SARA, FARS\u2013ADL, INAS, EQ-5D, SCAFI, and CCFS scales. Baseline measures included GAA repeats, frataxin expression in fibroblasts, CSF NfL, and disease burden. Frataxin levels were significantly reduced in patients and correlated with GAA1 length and baseline severity. SARA, FARS\u2013ADL, and INAS worsened significantly over time, while SCAFI and CCFS remained stable. GAA1 length and baseline SARA score emerged as the strongest predictors of progression. CSF NfL was elevated in younger patients and declined with age but did not correlate with severity or progression. These results support GAA1 length and baseline clinical status as robust predictors of progression and suggest limited utility of CSF NfL as a longitudinal biomarker particularly in later disease stages.\n                  <\/jats:p>","DOI":"10.1007\/s00415-026-13812-2","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T08:35:09Z","timestamp":1775723709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Longitudinal analysis shows GAA1 length and baseline clinical status as robust predictors of progression in Friedreich ataxia"],"prefix":"10.1007","volume":"273","author":[{"given":"Leire","family":"Manrique","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Mart\u00ednez-Dubarbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana L.","family":"Pelayo-Negro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Benitez-Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Victoria","family":"Sanchez-Pelaez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cota-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Loza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Martinez-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Irure-Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coro","family":"Sanchez-Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivelisse","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Matilla-Due\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4025-4606","authenticated-orcid":false,"given":"Jon","family":"Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"13812_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/brain\/104.3.589","volume":"104","author":"AE Harding","year":"1981","unstructured":"Harding AE (1981) Friedreich\u2019s ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 104:589\u2013620","journal-title":"Brain"},{"key":"13812_CR2","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","volume":"271","author":"V Campuzano","year":"1996","unstructured":"Campuzano V, Montermini L, Molt\u00f3 MD, Pianese L, Coss\u00e9e M, Cavalcanti F et al (1996) Friedreich\u2019s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271:1423\u20131427","journal-title":"Science"},{"issue":"Suppl 1","key":"13812_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00415-009-1002-3","volume":"256","author":"M Pandolfo","year":"2009","unstructured":"Pandolfo M (2009) Friedreich ataxia: the clinical picture. J Neurol 256(Suppl 1):3\u20138","journal-title":"J Neurol"},{"key":"13812_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2217\/nmt-2022-0011","volume":"12","author":"M Keita","year":"2022","unstructured":"Keita M, McIntyre K, Rodden LN, Schadt K, Lynch DR (2022) Friedreich ataxia: clinical features and new developments. Neurodegener Dis Manag 12:267\u2013283","journal-title":"Neurodegener Dis Manag"},{"issue":"2","key":"13812_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/1531-8249(199902)45:2<200::AID-ANA10>3.0.CO;2-U","volume":"45","author":"M Coss\u00e9e","year":"1999","unstructured":"Coss\u00e9e M, D\u00fcrr A, Schmitt M, Dahl N, Trouillas P, Allinson P et al (1999) Friedreich\u2019s ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol 45(2):200\u2013206","journal-title":"Ann Neurol"},{"key":"13812_CR6","doi-asserted-by":"publisher","DOI":"10.1042\/NS20200093","author":"DR Lynch","year":"2021","unstructured":"Lynch DR, Farmer G (2021) Mitochondrial and metabolic dysfunction in Friedreich ataxia: update on pathophysiological relevance and clinical interventions. Neuronal Signal. https:\/\/doi.org\/10.1042\/NS20200093","journal-title":"Neuronal Signal"},{"key":"13812_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40673-017-0062-x","volume":"4","author":"K B\u00fcrk","year":"2017","unstructured":"B\u00fcrk K (2017) Friedreich ataxia: current status and future prospects. Cerebellum Ataxias 4:4","journal-title":"Cerebellum Ataxias"},{"issue":"2","key":"13812_CR8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ana.25934","volume":"89","author":"DR Lynch","year":"2021","unstructured":"Lynch DR, Chin MP, Delatycki MB, Subramony SH, Corti M, Hoyle JC et al (2021) Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe study). Ann Neurol 89(2):212\u2013225","journal-title":"Ann Neurol"},{"key":"13812_CR9","first-page":"1703","volume":"37","author":"DR Lynch","year":"2022","unstructured":"Lynch DR, Chin MP, Boesch S, Delatycki MB, Giunti P, Goldsberry A et al (2022) Efficacy of omaveloxolone in Friedreich\u2019s ataxia: delayed-start analysis of the MOXIe extension. Mov Disord 37:1703\u20131713","journal-title":"Mov Disord"},{"key":"13812_CR10","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s40263-024-01113-z","volume":"38","author":"V Scott","year":"2024","unstructured":"Scott V, Delatycki MB, Tai G, Corben LA (2024) New and emerging drug and gene therapies for Friedreich ataxia. CNS Drugs 38:791\u2013805","journal-title":"CNS Drugs"},{"key":"13812_CR11","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1080\/14737175.2020.1821654","volume":"20","author":"TA Zesiewicz","year":"2020","unstructured":"Zesiewicz TA, Hancock J, Ghanekar SD, Kuo SH, Dohse CA, Vega J (2020) Emerging therapies in Friedreich\u2019s ataxia. Expert Rev Neurother 20:1215\u20131228","journal-title":"Expert Rev Neurother"},{"key":"13812_CR12","doi-asserted-by":"publisher","first-page":"e1499","DOI":"10.1212\/WNL.0000000000200913","volume":"99","author":"C Rummey","year":"2022","unstructured":"Rummey C, Corben LA, Delatycki M, Wilmot G, Subramony SH, Corti M et al (2022) Natural history of Friedreich ataxia. Neurology 99:e1499\u2013e1510","journal-title":"Neurology"},{"key":"13812_CR13","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/acn3.332","volume":"3","author":"M Patel","year":"2016","unstructured":"Patel M, Isaacs CJ, Seyer L, Brigatti K, Gelbard S, Strawser C et al (2016) Progression of Friedreich ataxia. Ann Clin Transl Neurol 3:684\u2013694","journal-title":"Ann Clin Transl Neurol"},{"key":"13812_CR14","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/acn3.225","volume":"2","author":"M Lazaropoulos","year":"2015","unstructured":"Lazaropoulos M, Dong Y, Clark E, Greeley NR, Seyer LA, Brigatti KW et al (2015) Frataxin levels in peripheral tissue in Friedreich ataxia. Ann Clin Transl Neurol 2:831\u2013842","journal-title":"Ann Clin Transl Neurol"},{"key":"13812_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017627","volume":"6","author":"F Sacc\u00e0","year":"2011","unstructured":"Sacc\u00e0 F, Puorro G, Antenora A, Marsili A, Denaro A, Piro R et al (2011) A combined nucleic acid and protein analysis in Friedreich ataxia. PLoS ONE 6:e17627","journal-title":"PLoS ONE"},{"key":"13812_CR16","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1002\/mds.30250","volume":"40","author":"C Rummey","year":"2025","unstructured":"Rummey C, Thomas-Black G, Garcia-Moreno H, Lynch DR, Abeti R, Arisoy H et al (2025) Increase of plasma biomarkers in Friedreich\u2019s ataxia. Mov Disord 40:1863\u20131873","journal-title":"Mov Disord"},{"key":"13812_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2018.00366","volume":"12","author":"AM Zeitlberger","year":"2018","unstructured":"Zeitlberger AM, Thomas-Black G, Garcia-Moreno H, Foiani M, Heslegrave AJ, Zetterberg H et al (2018) Plasma markers of neurodegeneration are raised in Friedreich\u2019s ataxia. Front Cell Neurosci 12:366","journal-title":"Front Cell Neurosci"},{"key":"13812_CR18","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1007\/s00415-020-09722-6","volume":"267","author":"SN Hayer","year":"2020","unstructured":"Hayer SN, Liepelt I, Barro C, Wilke C, Kuhle J, Martus P et al (2020) NfL and pNfH are increased in Friedreich\u2019s ataxia. J Neurol 267:1420\u20131430","journal-title":"J Neurol"},{"issue":"2","key":"13812_CR19","doi-asserted-by":"publisher","first-page":"fcac030","DOI":"10.1093\/braincomms\/fcac030","volume":"4","author":"M Corral-Juan","year":"2022","unstructured":"Corral-Juan M, Casquero P, Giraldo-Restrepo N et al (2022) New spinocerebellar ataxia subtype caused by SAMD9L mutation (SCA49). Brain Commun 4(2):fcac030","journal-title":"Brain Commun"},{"issue":"4","key":"13812_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1525-1578(10)60523-5","volume":"6","author":"P Ciotti","year":"2004","unstructured":"Ciotti P, Di Maria E, Bellone E, Ajmar F, Mandich P (2004) Triplet repeat primed PCR (TP PCR) in molecular diagnostic testing for Friedreich ataxia. J Mol Diagn 6(4):285\u2013289","journal-title":"J Mol Diagn"},{"key":"13812_CR21","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1474-4422(21)00027-2","volume":"20","author":"K Reetz","year":"2021","unstructured":"Reetz K, Dogan I, Hilgers RD et al (2021) Progression characteristics of EFACTS: a 4-year cohort study. Lancet Neurol 20:362\u2013372","journal-title":"Lancet Neurol"},{"key":"13812_CR22","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/S1474-4422(16)30287-3","volume":"15","author":"K Reetz","year":"2016","unstructured":"Reetz K, Dogan I, Hilgers RD et al (2016) Progression characteristics of EFACTS: a 2-year cohort study. Lancet Neurol 15:1346\u20131354","journal-title":"Lancet Neurol"},{"key":"13812_CR23","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1002\/acn3.51886","volume":"10","author":"L Porcu","year":"2023","unstructured":"Porcu L, Fichera M, Nanetti L et al (2023) Longitudinal changes of SARA scale in Friedreich ataxia. Ann Clin Transl Neurol 10:2000\u20132012","journal-title":"Ann Clin Transl Neurol"},{"key":"13812_CR24","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1177\/0883073812448462","volume":"27","author":"SR Regner","year":"2012","unstructured":"Regner SR, Wilcox NS, Friedman LS et al (2012) Friedreich ataxia clinical outcome measures. J Child Neurol 27:1152\u20131158","journal-title":"J Child Neurol"},{"issue":"4","key":"13812_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10048-020-00620-7","volume":"21","author":"M Santoro","year":"2020","unstructured":"Santoro M, Perna A, La Rosa P et al (2020) Compound heterozygosity for an expanded (GAA) and a (GAAGGA) repeat at FXN locus: from a diagnostic pitfall to potential clues to the pathogenesis of Friedreich ataxia. Neurogenetics 21(4):279\u2013287","journal-title":"Neurogenetics"},{"key":"13812_CR26","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1212\/WNL.49.2.606","volume":"49","author":"L Montermini","year":"1997","unstructured":"Montermini L, Kish SJ, Jiralerspong S, Lamarche JB, Pandolfo M (1997) Somatic mosaicism in Friedreich\u2019s ataxia. Neurology 49:606\u2013610","journal-title":"Neurology"},{"key":"13812_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189990","volume":"12","author":"A Long","year":"2017","unstructured":"Long A et al (2017) Somatic instability of the expanded GAA repeats. PLoS ONE 12:e0189990","journal-title":"PLoS ONE"},{"key":"13812_CR28","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/ana.22671","volume":"71","author":"MV Evans-Galea","year":"2012","unstructured":"Evans-Galea MV, Carrodus N, Rowley SM et al (2012) FXN methylation predicts expression and clinical outcome. Ann Neurol 71:487\u2013497","journal-title":"Ann Neurol"},{"key":"13812_CR29","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1007\/s00415-020-09868-3","volume":"267","author":"A Clay","year":"2020","unstructured":"Clay A, Obrochta KM, Soon RK, Russell CB, Lynch DR (2020) Neurofilament light chain as biomarker. J Neurol 267:2594\u20132598","journal-title":"J Neurol"},{"key":"13812_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e23347","volume":"10","author":"M Johnsson","year":"2024","unstructured":"Johnsson M, Zetterberg H, Blennow K, Lindberg C (2024) Plasma neurofilament in Friedreich ataxia. Heliyon 10:e24158","journal-title":"Heliyon"},{"key":"13812_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2011.01.010","volume":"303","author":"AH Koeppen","year":"2011","unstructured":"Koeppen AH (2011) Friedreich\u2019s ataxia: pathology and genetics. J Neurol Sci 303:1\u201312","journal-title":"J Neurol Sci"},{"key":"13812_CR32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/jnc.12303","volume":"126","author":"P Gonz\u00e1lez-Cabo","year":"2013","unstructured":"Gonz\u00e1lez-Cabo P, Palau F (2013) Mitochondrial pathophysiology in Friedreich\u2019s ataxia. J Neurochem 126:53\u201364","journal-title":"J Neurochem"},{"key":"13812_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2019.103419","volume":"102","author":"A Stepanova","year":"2020","unstructured":"Stepanova A, Magran\u00e9 J (2020) Mitochondrial dysfunction in neurons in Friedreich\u2019s ataxia. Mol Cell Neurosci 102:103419","journal-title":"Mol Cell Neurosci"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13812-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13812-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13812-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:43:39Z","timestamp":1779446619000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13812-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["13812"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13812-2","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Ethics Committee of Instituto de Investigaci\u00f3n Marqu\u00e9s de Valdecilla-IDIVAL, and written informed consent was obtained from all participants. Studies involving generation and use of human fibroblasts from skin biopsies was approved by the Research ethics committee of the Germans Trias I Pujol Research Institute and the University Hospital Germans Trias i Pujol in Badalona, Spain.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No generative AI was used to create or edit the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"AI use statement"}}],"article-number":"259"}}